Diaz-Rizo V, Enriquez-Luna A, Aguayo-Ruiz JI, Martinez-Ruiz MG, Zúńiga-Mora JA, Chávez-García D, Farias-Cuevas KP, Cardona-Muńoz EG, Nava-Zavala AH, Gámez-Nava JI, Gonzalez-Lopez L

Language: Spanish
References: 25
Page: 105-110
PDF size: 249.69 Kb.

ABSTRACT

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by polyarticular symmetrical inflammation, joint damage and the presence of autoantibodies that are associated with progressive incapacity and systemic complications. In Mexico, the prevalence of RA is 1.6%. Although multiple autoantibodies are observed in RA, just some of those have diagnostic interest or have been associated with disease progression. Antibodies against carbamylated proteins (anti-CarP) are directed to the carbamylated epitopes containing homocitrulline. The presence of anti-CarP in RA has been associated with worst joint damage and severe evolution of the disease. The present review aims to report the evidence on the frequency, diagnostic value and potential role of anti-CarP in erosions and other manifestations of RA severity.

REFERENCES

1. Bax M, Huizinga TW, Toes RE. The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. Semin Immunopathol. 2014; 36 (3): 313-325.

2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365 (23): 2205-2219.

3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001; 344 (12): 907-916.

4. Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M. Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis. 2002; 61 (10): 889-894.

5. Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Álvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011; 86: 3-8.

6. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005; 4 (3): 130-136.

7. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am. 2010; 36 (2): 385-404.

8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31 (3): 315-324.

9. Sanmartí R, Gómez-Puerta JA. Biomarkers in rheumatoid arthritis. Reumatol Clin. 2011; 6S3: S25-S28.

10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62 (9): 2569-2581.

11. Shi J, van Steenbergen HW, van Nies JA, Levarht EW, Huizinga TW, van der Helm-van Mil AH et al. The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Res Ther. 2015; 17: 339.

12. Gan RW, Trouw LA, Shi J, Toes RE, Huizinga TW, Demoruelle MK et al. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J Rheumatol. 2015; 42 (4): 572-579.

13. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Toes RE, Trouw LA et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2013; 65 (4): 911-915.

14. Trouw LA, Huizinga TW, Toes RE. Autoimmunity in rheumatoid arthritis: different antigens-common principles. Ann Rheum Dis. 2013; 72 Suppl 2: ii132-136.

15. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011; 108 (42): 17372-17377.

16. Sánchez-Ramón S, López-Longo FJ, Carreńo L. Interleukins network in rheumatoid arthritis pathophysiology: beyond proinflammatory cytokines. Reumatol Clin. 2011; 6S3: S20-S24.

17. Willemze A, Toes RE, Huizinga TW, Trouw LA. New biomarkers in rheumatoid arthritis. Neth J Med. 2012; 70 (9): 392-399.

18. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014; 73 (4): 780-783.

19. Jaisson S, Pietrement C, Gillery P. Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem. 2011; 57 (11): 1499-1505.

20. Mydel P, Wang Z, Brisslert M, Hellvard A, Dahlberg LE, Hazen SL et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol. 2010; 184 (12): 6882-6890.

21. Muller PC, Anink J, Shi J, Levarht EW, Reinards TH, Otten MH et al. Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. Ann Rheum Dis. 2013; 72 (12): 2053-2055.

22. Šenolt L, Grassi W, Szodoray P. Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis? BMC Med. 2014; 12: 49.

23. Ajeganova S, van Steenbergen HW, Verheul MK, Forslind K, Hafström I, Toes RE et al. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. Ann Rheum Dis. 2016; 26. pii: annrheumdis-2015-208870.

24. Brink M, Verheul MK, Rönnelid J, Berglin E, Holmdahl R, Toes RE et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther. 2015; 17: 25.

25. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007; 13 (10): 1176-1184.